Imagine a powerful medicine that doesn't work because it can't dissolve in water or gets stuck to proteins in the blood. This project creates a tiny, smart delivery vehicle that protects the drug and steers it directly to the bacteria and inflammation sites. It's like putting a GPS and a protective shell on a medicine that was previously too 'clunky' to be used.
Many potent antibiotic leads are abandoned because they cannot be formulated into a usable drug due to poor solubility. Meanwhile, MRSA and other resistant strains are increasing, threatening millions of lives and trillions in economic output.
A flexible, dual-targeting nanoparticle delivery platform. It converts insoluble drug leads into safe, targeted nano-formulations for MRSA treatment.
If you are a drug development firm dealing with promising lead compounds that failed clinical trials due to poor solubility—this project developed a nano-formulation platform that enables the delivery of these low-drugability leads. This allows you to revitalize a library of abandoned compounds for treating MRSA.
If you are a nano-medicine SME dealing with the challenge of delivering multiple drugs at once—this project developed a system for the co-delivery of synergistic combinations of antibiotics and potentiators. This increases the effectiveness of treatments against multidrug-resistant S. aureus.
If you are a clinical research unit dealing with high rates of MRSA in surgical sites and implants—this project developed a dual-targeting nanoparticle system. This targets both the pathogenic bacteria and areas of inflammation to improve patient outcomes in hospitalized settings.
Based on available project data, specific pricing or implementation costs are not provided.
The project focuses on developing the platform and demonstrating it with MRSA nano-formulations; however, industrial scaling details are not explicitly mentioned in the provided text.
Based on available project data, the project aims to develop broadly applicable targeting tools, but specific licensing terms are not listed.
The platform converts water-insoluble and protein-binding compounds into targeted nano-formulations, overcoming the 'low drugability' that typically causes leads to fail clinical trials.
The project period runs from 2022-03-01 to 2026-02-28, focusing on in vitro and in vivo safety demonstrations.
The consortium is a lean 3-partner group spanning Norway, Germany, and Poland. It features a strong research-heavy composition with 2 research organizations and 1 SME, resulting in a 33% industry ratio. This structure suggests a focus on high-risk, high-reward technical development led by SINTEF AS.
Contact SINTEF AS in Norway for platform licensing and collaboration.
Contact us to explore how this nano-formulation platform can rescue your abandoned drug leads.
